Financial Survey: OvaScience (OVAS) vs. Chromadex (CDXC)

Chromadex (NASDAQ: CDXC) and OvaScience (NASDAQ:OVAS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Profitability

This table compares Chromadex and OvaScience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chromadex -21.89% -47.30% -32.25%
OvaScience -20,090.13% -68.71% -60.49%

Insider & Institutional Ownership

6.1% of Chromadex shares are owned by institutional investors. Comparatively, 55.1% of OvaScience shares are owned by institutional investors. 11.6% of Chromadex shares are owned by company insiders. Comparatively, 9.5% of OvaScience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Chromadex has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Comparatively, OvaScience has a beta of 3.73, suggesting that its stock price is 273% more volatile than the S&P 500.

Earnings and Valuation

This table compares Chromadex and OvaScience’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chromadex $26.81 million 12.41 -$2.92 million ($0.23) -26.87
OvaScience $650,000.00 64.83 -$82.25 million ($1.83) -0.64

Chromadex has higher revenue and earnings than OvaScience. Chromadex is trading at a lower price-to-earnings ratio than OvaScience, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Chromadex and OvaScience, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chromadex 0 0 2 0 3.00
OvaScience 1 1 1 0 2.00

Chromadex presently has a consensus target price of $7.50, suggesting a potential upside of 21.36%. OvaScience has a consensus target price of $8.00, suggesting a potential upside of 577.97%. Given OvaScience’s higher possible upside, analysts plainly believe OvaScience is more favorable than Chromadex.

Summary

Chromadex beats OvaScience on 9 of the 14 factors compared between the two stocks.

Chromadex Company Profile

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

OvaScience Company Profile

OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply